Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: June 18, 2024
Reporting Period: Event-based report for June 18, 2024.
Business Context: The Company is an emerging growth company focused on biotechnology. This filing serves as a Regulation FD disclosure regarding a clinical trial milestone.
Key Financial Metrics
This Form 8-K is an event-driven report and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Clinical Trial Progress: The Company announced the completion of subject screening for its Pharmacokinetic (PK) Study. Consequently, the Company will begin dosing and sampling study subjects.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the PK Study progress. The disclosure is qualified in its entirety by the full text of that press release.
Risks and Contingencies: No specific risks or contingencies are detailed within the body of this 8-K filing. The document notes that the information is not deemed "filed" under the Exchange Act unless specifically incorporated by reference.
Investor Verification Checklist
- Verify the full text of the Press Release (Exhibit 99.1) for detailed study parameters and timelines.
- Confirm the status of the Pharmacokinetic (PK) Study dosing phase via subsequent company announcements.
- Review the Company's most recent 10-Q or 10-K for current financial liquidity and cash runway, as this 8-K contains no financial data.
- Monitor Nasdaq trading activity for the Common Stock (INBS) following this clinical milestone.